(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

By Nancy Lapid

(Reuters) -GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

U.S. researchers reviewed 10 years of medical records from 43,317 users and 43,315 similar nonusers of Novo Nordisk’s type 2 diabetes drugs Victoza and Ozempic or its weight-loss medication Wegovy, or Eli Lilly’s Mounjaro for diabetes or Zepbound for weight loss.

All volunteers were at risk for obesity-related cancers.

Each year, out of every thousand participants, 13.6 users of GLP-1 drugs were diagnosed with any of 14 types of cancer, compared to 16.6 nonusers, the researchers report

See Full Page